156 related articles for article (PubMed ID: 28342669)
21. Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge.
Hutchings CL; Birkett AJ; Moore AC; Hill AV
Infect Immun; 2007 Dec; 75(12):5819-26. PubMed ID: 17908809
[TBL] [Abstract][Full Text] [Related]
22. A highly infectious Plasmodium yoelii parasite, bearing Plasmodium falciparum circumsporozoite protein.
Zhang M; Kaneko I; Tsao T; Mitchell R; Nardin EH; Iwanaga S; Yuda M; Tsuji M
Malar J; 2016 Apr; 15():201. PubMed ID: 27068454
[TBL] [Abstract][Full Text] [Related]
23. Th1 immune response to Plasmodium falciparum recombinant thrombospondin-related adhesive protein (TRAP) antigen is enhanced by TLR3-specific adjuvant, poly(I:C) in BALB/c mice.
Mehrizi AA; Ameri Torzani M; Zakeri S; Jafary Zadeh A; Babaeekhou L
Parasite Immunol; 2018 Jul; 40(7):e12538. PubMed ID: 29799636
[TBL] [Abstract][Full Text] [Related]
24. Plasmodium falciparum sporozoite immunization protects against Plasmodium berghei sporozoite infection.
Sina BJ; do Rosario VE; Woollett G; Sakhuja K; Hollingdale MR
Exp Parasitol; 1993 Sep; 77(2):129-35. PubMed ID: 8375482
[TBL] [Abstract][Full Text] [Related]
25. Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus.
Urakami A; Sakurai A; Ishikawa M; Yap ML; Flores-Garcia Y; Haseda Y; Aoshi T; Zavala FP; Rossmann MG; Kuno S; Ueno R; Akahata W
Clin Vaccine Immunol; 2017 Jul; 24(7):. PubMed ID: 28515133
[TBL] [Abstract][Full Text] [Related]
26. A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses.
Jones RM; Chichester JA; Manceva S; Gibbs SK; Musiychuk K; Shamloul M; Norikane J; Streatfield SJ; van de Vegte-Bolmer M; Roeffen W; Sauerwein RW; Yusibov V
Hum Vaccin Immunother; 2015; 11(1):124-32. PubMed ID: 25483525
[TBL] [Abstract][Full Text] [Related]
27. Re-investigation of the circumsporozoite protein-based induction of sterile immunity against Plasmodium berghei infection.
Reed RC; Louis-Wileman V; Wells RL; Verheul AF; Hunter RL; Lal AA
Vaccine; 1996 Jun; 14(8):828-36. PubMed ID: 8817831
[TBL] [Abstract][Full Text] [Related]
28. A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate.
Noe AR; Espinosa D; Li X; Coelho-Dos-Reis JG; Funakoshi R; Giardina S; Jin H; Retallack DM; Haverstock R; Allen JR; Vedvick TS; Fox CB; Reed SG; Ayala R; Roberts B; Winram SB; Sacci J; Tsuji M; Zavala F; Gutierrez GM
PLoS One; 2014; 9(9):e107764. PubMed ID: 25247295
[TBL] [Abstract][Full Text] [Related]
29. Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses.
Khan F; Porter M; Schwenk R; DeBot M; Saudan P; Dutta S
PLoS One; 2015; 10(11):e0142035. PubMed ID: 26571021
[TBL] [Abstract][Full Text] [Related]
30. Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates.
Annoura T; Ploemen IH; van Schaijk BC; Sajid M; Vos MW; van Gemert GJ; Chevalley-Maurel S; Franke-Fayard BM; Hermsen CC; Gego A; Franetich JF; Mazier D; Hoffman SL; Janse CJ; Sauerwein RW; Khan SM
Vaccine; 2012 Mar; 30(16):2662-70. PubMed ID: 22342550
[TBL] [Abstract][Full Text] [Related]
31. A replicating adenovirus capsid display recombinant elicits antibodies against Plasmodium falciparum sporozoites in Aotus nancymaae monkeys.
Karen KA; Deal C; Adams RJ; Nielsen C; Ward C; Espinosa DA; Xie J; Zavala F; Ketner G
Infect Immun; 2015 Jan; 83(1):268-75. PubMed ID: 25368113
[TBL] [Abstract][Full Text] [Related]
32. Complete protection against P. berghei malaria upon heterologous prime/boost immunization against circumsporozoite protein employing Salmonella type III secretion system and Bordetella adenylate cyclase toxoid.
Tartz S; Rüssmann H; Kamanova J; Sebo P; Sturm A; Heussler V; Fleischer B; Jacobs T
Vaccine; 2008 Nov; 26(47):5935-43. PubMed ID: 18804138
[TBL] [Abstract][Full Text] [Related]
33. Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes.
Phares TW; May AD; Genito CJ; Hoyt NA; Khan FA; Porter MD; DeBot M; Waters NC; Saudan P; Dutta S
Malar J; 2017 Mar; 16(1):115. PubMed ID: 28288639
[TBL] [Abstract][Full Text] [Related]
34. Genetic vaccination against malaria infection by intradermal and epidermal injections of a plasmid containing the gene encoding the Plasmodium berghei circumsporozoite protein.
Weiss R; Leitner WW; Scheiblhofer S; Chen D; Bernhaupt A; Mostböck S; Thalhamer J; Lyon JA
Infect Immun; 2000 Oct; 68(10):5914-9. PubMed ID: 10992502
[TBL] [Abstract][Full Text] [Related]
35. Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection.
Foquet L; Hermsen CC; van Gemert GJ; Van Braeckel E; Weening KE; Sauerwein R; Meuleman P; Leroux-Roels G
J Clin Invest; 2014 Jan; 124(1):140-4. PubMed ID: 24292709
[TBL] [Abstract][Full Text] [Related]
36. Cross-species immunity following immunization with a circumsporozoite protein-based vaccine for malaria.
Yadava A; Nurmukhambetova S; Pichugin AV; Lumsden JM
J Infect Dis; 2012 May; 205(9):1456-63. PubMed ID: 22457289
[TBL] [Abstract][Full Text] [Related]
37. Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate.
Milich DR; Hughes J; Jones J; Sällberg M; Phillips TR
Vaccine; 2001 Dec; 20(5-6):771-88. PubMed ID: 11738741
[TBL] [Abstract][Full Text] [Related]
38. Protective Efficacy Induced by Genetically Attenuated Mid-to-Late Liver-Stage Arresting Plasmodium berghei Δmrp2 Parasites.
van der Velden M; Rijpma SR; Verweij V; van Gemert GJ; Chevalley-Maurel S; van de Vegte-Bolmer M; Franke-Fayard BM; Russel FG; Janse CJ; Sauerwein RW; Koenderink JB
Am J Trop Med Hyg; 2016 Aug; 95(2):378-82. PubMed ID: 27296385
[TBL] [Abstract][Full Text] [Related]
39. Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites.
Mizutani M; Iyori M; Blagborough AM; Fukumoto S; Funatsu T; Sinden RE; Yoshida S
Infect Immun; 2014 Oct; 82(10):4348-57. PubMed ID: 25092912
[TBL] [Abstract][Full Text] [Related]
40. Design and assessment of TRAP-CSP fusion antigens as effective malaria vaccines.
Lu C; Song G; Beale K; Yan J; Garst E; Feng J; Lund E; Catteruccia F; Springer TA
PLoS One; 2020; 15(1):e0216260. PubMed ID: 31967991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
